🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome

Recruitingn/aAges 28 Weeks - 36 WeeksAllTanta University
NCT07154134 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Prematurity. * Gestational age between 28 and 36 weeks. * Suffering from respiratory distress syndrome. Exclusion Criteria: * Intrauterine growth restriction (IUGR). * Hypoxic ischemic encephalopathy. * Multiple congenital anomalies. * Chromosomal abnormalities. * Preterm less than 28 weeks. * Neonates with a maternal history of chorioamnionitis (early sepsis). * Infant of diabetic mother. * Prelabor rupture of membranes (PROM)\> 2 hours.
💊

What it tests

  • Serum endocan
  • Serum copeptin
📍

Where

1 site
Tanta University
Tanta, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy